1. Home
  2. VRTX vs COP Comparison

VRTX vs COP Comparison

Compare VRTX & COP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

HOLD

Current Price

$441.30

Market Cap

115.7B

Sector

Technology

ML Signal

HOLD

Logo ConocoPhillips

COP

ConocoPhillips

HOLD

Current Price

$121.48

Market Cap

136.5B

Sector

Energy

ML Signal

HOLD

Company Overview

Basic Information
Metric
VRTX
COP
Founded
1989
1917
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Integrated oil Companies
Sector
Technology
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
115.7B
136.5B
IPO Year
2006
2005

Fundamental Metrics

Financial Performance
Metric
VRTX
COP
Price
$441.30
$121.48
Analyst Decision
Buy
Buy
Analyst Count
29
22
Target Price
$539.69
$123.59
AVG Volume (30 Days)
1.2M
8.6M
Earning Date
05-04-2026
04-30-2026
Dividend Yield
N/A
2.83%
EPS Growth
836.54
N/A
EPS
15.32
6.35
Revenue
$2,488,652,000.00
$58,944,000,000.00
Revenue This Year
$10.81
$1.23
Revenue Next Year
$10.41
$2.12
P/E Ratio
$28.88
$18.72
Revenue Growth
46.20
7.67
52 Week Low
$362.50
$84.28
52 Week High
$510.77
$135.87

Technical Indicators

Market Signals
Indicator
VRTX
COP
Relative Strength Index (RSI) 44.66 46.08
Support Level $427.52 $91.18
Resistance Level $442.22 $122.50
Average True Range (ATR) 10.82 3.79
MACD 0.78 -1.85
Stochastic Oscillator 55.61 21.57

Price Performance

Historical Comparison
VRTX
COP

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

About COP ConocoPhillips

ConocoPhillips is a US-based independent exploration and production firm. Its operations are primarily in Alaska and the Lower 48, with footprints in Canada, Europe, Asia-Pacific, the Middle East, and Africa. It also has substantial integrated LNG production and marketing activities across geographies.

Share on Social Networks: